Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial presented as a 250 mg atovaquone / 100 mg proguanil tablet for oral use. It prevents malaria infection and treats acute uncomplicated malaria in travelers and residents of endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is used in the prevention and treatment of malaria, a parasitic disease transmitted by Anopheles mosquitoes. - Malaria prophylaxis: prevents infection in travelers and residents entering endemic areas. - Acute uncomplicated malaria (Plasmodium falciparum, vivax, ovale, malariae): clears parasites and resolves symptoms. - Chemoprophylaxis for chloroquine‑resistant malaria: provides effective protection where standard prophylaxis fails.

Malarone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramp‑like discomfort in the abdomen. - Dizziness: sensation of light‑headedness. - Loss of appetite: reduced desire to eat. - Vomiting: occasional emesis.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hematologic abnormalities: neutropenia or anemia. - Hypersensitivity reactions: rash, fever, or anaphylaxis. - Hemolytic anemia: especially in patients with G6PD deficiency.

Before prescribing Malarone, consider the following precautions to ensure safe use. - Pregnancy: Category B, use only if benefit outweighs risk. - Renal impairment: dose adjustment may be required in severe kidney dysfunction. - Hepatic impairment: monitor liver function tests during therapy. - Known hypersensitivity: avoid in patients allergic to atovaquone, proguanil, or related compounds. - Concomitant medications: assess for interactions that may increase toxicity or reduce efficacy. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Malarone can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Rifampin: induces metabolism, markedly reduces atovaquone and proguanil levels, compromising efficacy. - Cimetidine: increases atovaquone concentrations, raising risk of toxicity. - Other antimalarials (e.g., mefloquine): combined use may increase neuropsychiatric adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Anticonvulsants (e.g., carbamazepine, phenytoin): may lower drug levels, reducing effectiveness. - Statins (e.g., simvastatin): increased risk of myopathy when used together. - HIV protease inhibitors (e.g., atazanavir): may alter atovaquone exposure, necessitating clinical observation.